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http://www.biomedcentral.com/1472-6963/13/3RESEARCH ARTICLE Open AccessSocioeconomic differences in mortality amenable
to health care among Finnish adults 1992-2003:
12 year follow up using individual level linked
population register data
Alison K McCallum1*, Kristiina Manderbacka2, Martti Arffman2, Alastair H Leyland3 and Ilmo Keskimäki2,4Abstract
Background: Finland decentralised its universal healthcare system and introduced market reforms in the 1990s.
Despite a commitment to equity, previous studies have identified persistent socio-economic inequities in
healthcare, with patterns of service use that are more pro-rich than in most other European countries. To examine
whether similar socio-economic patterning existed for mortality amenable to intervention in primary or specialist
care, we investigated trends in amenable mortality by income group from 1992-2003.
Methods: We analysed trends in all cause, total disease and mortality amenable to health care using individual
level data from the National Causes of Death Register for those aged 25 to 74 years in 1992-2003. These data were
linked to sociodemographic data for 1990-2002 from population registers using unique personal identifiers. We
examined trends in causes of death amenable to intervention in primary or specialist healthcare by income
quintiles.
Results: Between 1992 and 2003, amenable mortality fell from 93 to 64 per 100,000 in men and 74 to 54 per
100,000 in women, an average annual decrease in amenable mortality of 3.6% and 3.1% respectively. Over this
period, all cause mortality declined less, by 2.8% in men and 2.5% in women. By 2002-2003, amenable mortality
among men in the highest income group had halved, but the socioeconomic gradient had increased as amenable
mortality reduced at a significantly slower rate for men and women in the lowest income quintile. Compared to
men and women in the highest income quintile, the risk ratio for mortality amenable to primary care had increased
to 14.0 and 20.5 respectively, and to 8.8 and 9.36 for mortality amenable to specialist care.
Conclusions: Our findings demonstrate an increasing socioeconomic gradient in mortality amenable to
intervention in primary and specialist care. This is consistent with the existing evidence of inequity in healthcare use
in Finland and provides supporting evidence of changes in the socioeconomic gradient in health service use and in
important outcomes. The potential adverse effect of healthcare reform on timely access to effective care for people
on low incomes provides a plausible explanation that deserves further attention.
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Over the past fifty years, improved living conditions and
comprehensive health services have reduced rates of pre-
mature death [1-3]. One aspect of health system per-
formance is the variation in amenable mortality,
premature deaths that should be avoided by timely and
effective health service intervention [4]. Lists of causes
of amenable mortality have been refined over time to re-
flect increased availability of effective interventions and
the impact of health system factors on outcomes. To
understand better the relationship between healthcare
and amenable mortality, studies have tried to distinguish
between mortality amenable to prevention, for example,
immunisation, chronic disease management delivered
largely in primary care, and interventions undertaken by
specialist services [5-7].
Nolte and McKee found that Finland had higher amen-
able mortality rates than many comparable countries with
only Ireland, United Kingdom and Portugal having higher
rates [1]. Between 1997-8 and 2003-3 the rate fell by more
than 20%. In Finland there is evidence of widespread socio-
economic differences in use of services [8-10] quality of
care [9,11,12] and outcomes [11,13,14]. Equity in health
care and reducing premature death from amenable causes
are important objectives of health policy for all countries.
Few studies, however, have examined changes in amenable
mortality over time by socioeconomic status [15-17] or edu-
cation [18] by type or place of intervention. Since socioeco-
nomic inequities in access to and provision of services
remain problematic, this is a significant gap in the literature.
As socio-economic differences in amenable mortality
are a potential consequence of the inverse care law [19],
an understanding of the context in which prevention
and treatment is delivered is important. In Finland, a com-
prehensive healthcare system based on a network of pri-
mary healthcare centres linked to municipalities was
established in 1972 [20]. The recession of the 1990s halted
the expansion in primary care and preventive services
[21,22] a market in the provision of primary care devel-
oped and private sector specialist ambulatory care services
expanded. These services were available primarily to those
in regular employment, with others reliant on municipal
health centres. The recession also coincided with devolu-
tion of health service strategy to municipalities and, while
there were attempts to introduce markets and commis-
sioning with tight control over activity and budgets [23],
most municipalities had limited influence over the increas-
ing costs in specialist care. While many countries have
adopted similar reforms, the Finnish experience is import-
ant for three reasons.
1) Socio-economic inequities in access to care [8,24,25]
appear greater in Finland than in many other high
income countries2) Despite structural and health service changes,
Finland retained substantial social welfare
programmes. While income inequalities rose
between 1992 and 2004 [23], they remained lower
than in the United Kingdom or Sweden.
3)Welfare interventions, such as help with housing and
daily living costs, reduced the potential for changes
in access to social care to affect premature mortality,
particularly causes amenable to primary care, despite
the reduction in the income share received by those
with the lowest incomes. [26].
This study analyses changes in the socioeconomic distri-
bution of mortality amenable to primary prevention, early
detection and improved treatment and medical care be-
tween 1992 and 2003 in Finland. During this period of
economic recession, subsequent boom, and structural
change in Finland, health service expenditure declined
then slowly recovered, hospital productivity increased and
patient co-payments rose [21]. Based on existing evidence
of inequities in the access to and provision of services,
mortality from specific causes amenable to health care
and the changes in the Finnish health care system over the
study period, we hypothesised that amenable mortality
would be patterned by income. We also aimed to examine
how the balance between mortality amenable to preven-
tion, early intervention and treatment, and improved
treatment and medical care in primary and specialist set-
tings would change over time.
Methods
Classification of causes of death
Statistics Finland extracted individual data from the causes
of death register for all deaths in the Finnish population
aged 25-74 years between 1992 and 2003. The resident
population aged 25-74 years formed the population at risk.
The period studied covered the transition from ICD9 to
ICD10 in 1996. Statistics Finland developed and validated
procedures for forward and back translation. The com-
pleteness of death registration, the process for expert re-
view of disputed cases and the high autopsy rate for
deaths from suspicious and external causes together pro-
vide high quality mortality data [27].
Classification of amenable mortality
We classified deaths amenable to health care based on
the Nolte and McKee list [1,2]. We included premature
death from chronic obstructive pulmonary disease
(COPD); a category that includes chronic bronchitis and
emphysema. In Finland, premature deaths classified as
being primarily due to COPD are rare. Inclusion of this
category reflects work undertaken by researchers in New
Zealand, supported by an international expert reference
group [28]. This reflects recognition that, while COPD is
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ventions available in primary care include active chronic
disease management: prevention of exacerbations through
smoking cessation and immunization against influenza and
pneumococcal disease, rapid treatment and pulmonary re-
habilitation. We analysed deaths from ischaemic heart
disease separately. To take account of the small number of
deaths from individual conditions, we grouped them by
whether they were mainly amenable to individual prevent-
ive services, early detection and intervention, and improved
treatment and medical care [5]. We further subdivided the
improved treatment and medical care group into whether
treatment was undertaken mostly in primary or specialist
care [2,29,30] (see Additional file 1: Appendix 1).
We included conditions amenable to primary preven-
tion by the health care system such as infections that are
preventable by hygiene measures or by immunisation.
Although these interventions have a population-level im-
pact, individual patients receive these services from pri-
mary care. Deaths amenable to early detection and
intervention include tuberculosis; patients with symp-
toms of these conditions require rapid access to diagno-
sis and treatment. Similarly, while not all premature
deaths from hypertension, cerebrovascular disease or
cancers with a detectable pre-malignant stage are pre-
ventable, the amenable mortality rate can be reduced by
prompt identification and effective, protocol based inter-
vention. Mortality amenable to improved treatment and
medical care comprises those conditions where the like-
lihood of death without treatment is high and includes
diabetes and thyroid disease (where most treatment is in
primary care). These are chronic diseases for which a
combination of medication, active follow-up and second-
ary prevention reduces the risk of adverse events. By
comparison, conditions amenable to specialist care in-
clude cancers without an obvious preventable cause such
as cancer of the testis, where treatment in a specialist
centre produces high cure rates.
We ran the analyses for all cause, total disease and
amenable mortality. We did not categorise separately
deaths amenable to health policy, such as those related
to substance misuse. We were unable to include deaths
due to “accident or misadventure due to healthcare” as
these are not classified separately in Finnish routine
datasets on causes of death. Such deaths usually repre-
sent a small fraction of all amenable mortality [2].
Income data
We studied amenable mortality by family net income in
adults (25-74 years). Income data from annual tax statistics
were linked to individuals by personal identification codes.
To avoid indirect identification of rare events, Statistics
Finland tabulated annual data by socio-demographic vari-
ables. Age was classified into five year age bands andincome was adjusted for family size using the OECD
equivalence scale and grouped according to quintile limits
derived from the population at risk [30]. Those with no
recorded income were assigned to the lowest income group.
Income was linked to individuals based on income during
the previous calendar year for the entire population at risk.
Statistical methods
We directly age-standardized mortality rates in 1992-93
and 2002-03 for total and subgroups of amenable mor-
tality using the European standard population. Annual
age-standardized mortality rates were calculated by in-
come quintile. We examined trends in amenable mortal-
ity by income quintiles using a repeated cross-sectional
design, with the count of deaths in cells defined by in-
come quintile, age group and year modelled using Pois-
son regression and including an interaction between
income and year. All models were stratified by sex.
Trends
While the main focus was of our work was on relative in-
equalities, we examined trends over time in the absolute
levels of socioeconomic patterning of amenable mortality
by reviewing the numbers of deaths, evaluating changes in
the age-standardised amenable mortality rate and calculat-
ing the reduction in the average amenable mortality rate
by income quintile. Average annual changes were obtained
from estimates of linear time trends in age-adjusted
repeated measures Poisson regression models.
To assess differences in amenable mortality by income
quintile we examined data in three four-year periods
(1992-1995, 1996-1999 and 2000-2003). Again, we mod-
elled mortality rates using Poisson regression models but
with these periods in place of the individual year. Rate
ratios for contrasts were used to describe the relative mag-
nitude of amenable mortality in lower income quintiles
compared to the highest one in each of the three periods
[31]. Further, we determined the annual contribution of
mortality amenable to the place of intervention: primary
and specialist care, and to the type of intervention: individ-
ual preventive services, early detection and intervention,
and improved treatment and medical care to differences
in total amenable mortality between the highest and low-
est income quintiles. To minimise potential misclassifica-
tion of income or amenability associated with serious
underlying disease, we also analysed income differences
excluding patients resident in long-term institutions.
Statistical analyses were performed using SAS System
for Windows, release 9.1.3. [32].
Results
During the study period, the total number of deaths in
people aged 25-74 years declined from a two year aver-
age of 21609 in 1992-93 to a two year average of 18719
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causes) reduced from 18430 to 15994. The number of
deaths per year classified as amenable among men and
women aged 25 to 74 years decreased from a two year
average of 4072 in 1992-1993 to 3265 in 2002-2003.
Table 1 illustrates the reduction in all cause, total disease
and amenable mortality.
Amenable mortality decreased more rapidly than all
cause and total disease mortality. Among men in 2002-
03, amenable mortality accounted for 13% of total mor-
tality and 16% of disease mortality, among women the
figures were 26% and 28%. The average annual reduction
in amenable mortality (3.6%) was greater than that for
all cause (2.8%) and total disease mortality (3.0%) for
men. Among women the reduction was more modest.
The annual average decline in amenable mortality acrossTable 1 Age-standardized amenable mortality rate for 100,00
mortality (years 1992-93 and 2002-03) and average annual ch
1992-93
avg number
of deaths
per year
Mortality
rate
%
am
mo
Men
All cause mortality 14038 990
Total disease mortality 11557 828
Total amenable mortality 2032 144 100
Primary prevention 0 0 0.1
Early detection and intervention 1358 97 67.
- tuberculosis 40 3 2.0
- malignant neoplasm 273 20 13.
- hypertension and cerebrovascular disease 1046 75 52.
Improved treatment and medical care 674 46 32.
- Predominantly primary care 105 6 4.4
- Predominantly specialist care 569 40 27.
Ischaemic heart disease 4188 303
Women
All cause mortality 7571 420
Total disease mortality 6873 377
Total amenable mortality 2040 114 100
Primary prevention 0 0
Early detection and intervention 1653 93 81.
- tuberculosis 22 1 1.0
- malignant neoplasm 782 47 40.
- Hypertension and cerebrovascular disease 849 45 39.
Improved treatment and medical care 387 21 18.
- Predominantly primary care 49 3 2.6
- Predominantly specialist care 338 18 15.
Ischaemic heart disease 1573 80
* Due to small numbers RRs were not estimated.
** Due to few deaths in younger age bands 25-44 years old were combined into othe study period was 3.1%, compared with 2.6% for all
cause and for total disease mortality. The annual average
decline in amenable mortality showed a socioeconomic
gradient; in the highest income group this was -5.9%
(95% CI -6.7 to -5.8) for men and -4.1% (95% CI -5.1 to
-3.1) for women, whereas in the lowest income group
the annual average decline was -0.9% (95% CI -2.0 to
0.2) for men and -1.0 (95% CI -2.3 to -0.3) for women.
The largest subgroups of amenable mortality comprised
conditions suitable for early detection and intervention
(66% of total amenable mortality among men in 1992-93,
and 80% among women). Mortality amenable to improved
treatment and medical care comprised 33% of amenable
deaths among men and 20% among women. By 2002-
2003, deaths amenable to improved treatment and medical
intervention in primary care comprised 5% of amenable0 population aged 25-74, proportion of total amenable
anges (%)
2002-03 Average annual
change
of total
enable
rtality
avg number
of deaths
per year
Mortality
rate
Amenable
mortality
% 95%CI
12512 739 -2.8 ( -3.0 - -2.7)
10395 611 -3.0 ( -3.1 - -2.8)
1678 99 100 -3.6 ( -4.0 - -3.2)
0 0 *
7 1137 67 67.6 -3.7 ( -4.2 - -3.3)
18 1 1.0 -10.0** (-13.1 - -6.9)
7 289 17 17.2 -1.3 ( -2.2 - -0.3)
0 831 49 49.3 -4.3 ( -4.8 - -3.8)
3 541 32 32.4 -3.3 ( -3.9 - -2.6)
84 5 5.1 -1.3 ( -3.1 - 0.4)
9 457 27 27.3 -3.6 ( -4.3 - -2.9)
2926 172 -5.6 ( -5.9 - -5.3)
6207 324 -2.6 ( -2.8 - -2.4)
5599 289 -2.6 ( -2.8 - -2.4)
1587 83 100 -3.1 ( -3.5 - -2.7)
0 0 *
4 1320 69 83.0 -3.0 ( -3.5 - -2.6)
9 0 0.5 -6.7** (-10.7 - -2.7)
8 756 40 48.7 -1.0 ( -1.6 - -0.4)
6 556 28 33.8 -5.4 ( -6.0 - -4.7)
6 267 14 17.0 -3.2 ( -4.1 - -2.3)
43 3 3.1 -1.1 ( -3.5 - 1.3)
9 224 12 13.9 -3.5 ( -4.5 - -2.6)
844 41 -6.8 ( -7.3 - -6.4)
ne age-group for RR estimates.
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responsive to intervention in secondary care accounted
for 29% of amenable mortality among men and 17%
among women.
In 1992-93, the start of our study period, ischaemic
heart disease (IHD) comprised 30% of total mortality
and 36% of disease mortality among men aged 25-
74 years. Among women, IHD mortality accounted for
19% of total mortality and 22% of disease mortality. Be-
tween 1992-2003 the annual number of ischaemic heart
disease deaths declined from 5761 to 3771, from 192 to
109 per 100,000 among men, and from 51 to 26 per
100,000 in women. The average annual reduction in
mortality attributed to ischaemic heart disease was
5.6% in men (95% CI 5.9 to -5.3%) and 6.8% among
women (7.3 to -6.4%).
All income groups and both genders experienced an
average annual reduction in premature mortality attribut-
able to ischaemic heart disease that was greater than that
for amenable mortality excluding IHD. The average an-
nual reduction was -7.9 (95% 8.6 to 7.1) among men and
-7.2 (95% CI -9.7 to -4.7) among women in the highest in-
come group compared with -2.3 (95% CI -3.2 to -1.5)
among men and -3.8 (95% CI -4.8 to -2.8) among women
in the lowest income group.
Tables 2 (men) and 3 (women) present the gradient
in risk ratios for amenable mortality by income in the
three periods. The annual rate of change appeared
fairly linear and while the pattern differed by income
group, none of the rules for using this approach were
violated. Among men, the gradient in amenable mortal-
ity across income groups was similar to that found in
all cause and total disease mortality. The gradients
increased from the early 1990s to early 2000s. The rate
ratios by income in mortality amenable to early detec-
tion and intervention were more modest but followed a
similar trend, increasing from 2.00 in 1992-3 to 2.66 in
2002-3. Relative income differences were considerably
larger for mortality amenable to improved treatment
and medical care than those found for all cause (2.53 in
1992-3 to 3.26 in 2002-3) or disease mortality in the
lowest income group (1.20 (not significant) in 1992-3
to 2.91 in 2002-2003). The gradient in mortality amen-
able to improved treatment and medical care also
increased over the study period. In 1992-3, the risk
ratio for mortality amenable to improved treatment
and medical care in primary care was 5.87 and 5.31 for
treatment in specialist settings. By 2002-03, the relative
mortality risk of men in the lowest income group was
14 times that of the highest income group for mortality
amenable to primary care and just less than nine times
for mortality amenable to specialist care.
Among women, the income gradient was generally less
pronounced than for men although exceptions were seenfor mortality amenable to improved treatment and med-
ical care. Here the rate ratio in the lowest income group
was 20.54 times that of the highest income group for
primary care and 10.36 for specialist care by 2000-2003.
There was no significant gradient for cancer at the
start of the study period. The gradient remained modest
relative to other conditions but it increased to 1.31 for
men and 1.57 for women by 2003. While the mix of can-
cers was different for men and women, cancer is an im-
portant source of amenable mortality for women
comprising 40% in 1992, rising to 48% of total amenable
mortality by 2003.
The gradient in premature mortality attributed to is-
chaemic heart disease was similar to that found when all
categories of amenable mortality were combined. As was
found for amenable mortality, the income gradient for
ischaemic heart disease increased significantly, albeit
more modestly, over time (p < 0.01).
Figure 1 shows that amenable mortality declined in men
and women in all income groups. By 2003 the gender gap
had disappeared for those in the highest and second high-
est income group. Overall amenable mortality in men in
the highest income group (50.98 per 100,000) was lower
than that for women (53.85 per 100,000). The excess
amenable mortality in men persisted for those in the low-
est income group; in 2003 the rate in men was 1.44 times
that in women. The decline in amenable mortality in men
and women in the lowest income group between 1992-
2003 was modest, around 11% (from 237.23 per 100,000
in 1992 to 212.96 in 2003), while the rate halved for men
in the highest income group (from 103.99 in 1992 50
50.98 in 2003). Reanalysing the data excluding individuals
resident in long term institutions decreased income gradi-
ents a little, but did not alter the findings.
Discussion
Analysis of comprehensive, individual level data demon-
strated that amenable mortality in Finland varied system-
atically by income group between 1992 and 2003: the
lower the income, the higher the risk of amenable mortal-
ity. During this period, the absolute and relative gap be-
tween the highest and lowest income groups widened with
an excess of 28.74 amenable deaths per 100,000 among
men in 2003 compared with 1992. Income related differ-
ences were particularly high for mortality amenable to
improved treatment and medical care in primary health-
care. Towards the end of the study period, the risk ratio
for amenable mortality for the lowest income quintile was
14 times that of the highest quintile for men and 21 times
that for women. These large risk ratios reflect very few
deaths from causes such as asthma, diabetes or epilepsy
among the richest quintile.
The socio-economic gradient in amenable mortality
increased, with limited reductions in the age-standardized
Table 2 Socioeconomic gradients in risk ratios for amenable mortality by income and cause of death, men aged 25-74
Period I: 1992 – 95 Period II: 1996 - 99 Period III: 2000 - 03 Period interactions
Income RR 95% CI RR 95% CI RR 95% CI p value
All cause mortality
5 1.00 1.00 1.00 PI vs PII <.001
4 1.35 (1.18 - 1.54 ) 1.39 (1.20 - 1.61 ) 1.41 (1.23 - 1.61 ) PII vs PIII <.001
3 1.67 (1.49 - 1.88 ) 1.77 (1.55 - 2.02 ) 1.80 (1.58 - 2.04 ) PI vs PIII <.001
2 2.15 (1.89 - 2.44 ) 2.41 (2.10 - 2.77 ) 2.60 (2.26 - 3.00 )
1 2.89 (2.54 - 3.28 ) 3.49 (3.03 - 4.03 ) 4.17 (3.57 - 4.88 )
Total disease mortality
5 1.00 1.00 1.00 PI vs PII <.001
4 1.36 (1.19 - 1.57 ) 1.41 (1.22 - 1.64 ) 1.42 (1.24 - 1.63 ) PII vs PIII <.001
3 1.67 (1.47 - 1.89 ) 1.77 (1.54 - 2.03 ) 1.81 (1.59 - 2.06 ) PI vs PIII <.001
2 2.07 (1.81 - 2.38 ) 2.32 (2.01 - 2.769) 2.53 (2.17 - 2.94 )
1 2.59 (2.28 - 2.95 ) 3.18 (2.73 - 3.71 ) 3.82 (3.23 - 4.52 )
Total amenable mortality
5 1.00 1.00 1.00 PI vs PII <.001
4 1.20 (0.99 - 1.45 ) 1.46 (1.19 - 1.78 ) 1.35 (1.10 - 1.66 ) PII vs PIII 0.09
3 1.46 (1.23 - 1.73 ) 1.68 (1.42 - 1.99 ) 1.65 (1.39 - 1.97 ) PI vs PIII <.001
2 1.90 (1.59 - 2.267) 2.31 (1.91 - 2.80 ) 2.43 (1.98 - 2.97 )
1 2.83 (2.40 - 3.33 ) 3.91 (3.27 - 4.68 ) 4.13 (3.37 - 5.06 )
Early detection and intervention
5 1.00 1.00 1.00 PI vs PII <.001
4 1.11 (0.94 - 1.29 ) 1.37 (1.18 - 1.60 ) 1.28 (1.08 - 1.53 ) PII vs PIII 0.49
3 1.31 (1.14 - 1.50 ) 1.53 (1.35 - 1.74 ) 1.47 (1.27 - 1.70 ) PI vs PIII <.001
2 1.61 (1.40 - 1.85 ) 1.87 (1.61 - 2.19 ) 1.98 (1.66 - 2.35 )
1 2.00 (1.75 - 2.27 ) 2.67 (2.26 - 3.16 ) 2.66 (2.25 - 3.15 )
- malignant neoplasm
5 1.00 * 1.00 1.00 PI vs PII 0.09
4 0.85 (0.66 - 1.08 ) 1.10 (0.94 - 1.28 ) 1.05 (0.85 - 1.31 ) PII vs PIII 0.05
3 0.78 (0.63 - 0.97 ) 1.12 (0.97 - 1.29 ) 1.02 (0.85 - 1.21 ) PI vs PIII 0.46
2 0.98 (0.79 - 1.21 ) 1.18 (1.03 - 1.35 ) 1.21 (1.03 - 1.41 )
1 0.90 (0.75 - 1.08 ) 1.25 (1.01 - 1.55 ) 1.31 (1.04 - 1.64 )
- hypertension and cerebrovascular disease
5 1.00 1.00 1.00 PI vs PII <.001
4 1.21 (1.03 - 1.43 ) 1.51 (1.27 - 1.79 ) 1.41 (1.13 - 1.76 ) PII vs PIII 0.25
3 1.52 (1.32 - 1.75 ) 1.71 (1.49 - 1.97 ) 1.72 (1.43 - 2.05 ) PI vs PIII <.001
2 1.85 (1.60 - 2.15 ) 2.19 (1.85 - 2.59 ) 2.39 (1.94 - 2.96 )
1 2.37 (2.06 - 2.72 ) 3.23 (2.72 - 3.84 ) 3.35 (2.75 - 4.07 )
-Improved treatment and medical care
5 1.00 1.00 1.00 PI vs PII <.001
4 1.46 (1.07 - 1.97 ) 1.69 (1.20 - 2.39 ) 1.57 (1.18 - 2.08 ) PII vs PIII 0.03
3 1.87 (1.41 - 2.48 ) 2.09 (1.50 - 2.21 ) 2.25 (1.74 - 2.92 ) PI vs PIII <.001
2 2.77 (2.06 - 3.71 ) 3.74 (2.75 - 5.09 ) 4.01 (3.06 - 5.26 )
1 5.47 (4.16 - 7.19 ) 7.93 (5.93 - 10.6 ) 9.43 (7.32 - 12.1 )
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(Continued)
- predominantly primary care
5 1.00 1.00 1.00 PI vs PII 0.07
4 1.95 (1.29 - 2.93 ) 1.54 (1.02 - 2.32 ) 2.14 (1.18 - 3.88 ) PII vs PIII 0.06
3 2.61 (1.84 - 3.72 ) 2.18 (1.39 - 3.43 ) 4.01 (2.32 - 6.93 ) PI vs PIII <.001
2 3.90 (2.79 - 5.44 ) 5.07 (3.20 - 8.02 ) 6.66 (3.84 - 11.5 )
1 5.87 (4.00 - 8.62 ) 7.84 (5.09 - 12.0 ) 14.00 (8.25 - 23.8 )
- predominantly specialist care
5 1.00 1.00 1.00 PI vs PII <.001
4 1.35 (0.97 - 1.87 ) 1.71 (1.19 - 2.45 ) 1.47 (1.08 - 2.01 ) PII vs PIII 0.06
3 1.73 (1.27 - 2.34 ) 2.05 (1.42 - 2.95 ) 2.04 (1.56 - 2.67 ) PI vs PIII <.001
2 2.57 (1.88 - 3.51 ) 3.54 (2.56 - 4.90 ) 3.69 (2.80 - 4.87 )
1 5.31 (3.97 - 7.11 ) 7.95 (5.88 - 10.8 ) 8.77 (6.76 - 11.4 )
Ischaemic heart disease (IHD)
5 1.00 1.00 1.00 PI vs PII 0.115*
4 1.59 ( 1.19 -2.12) 1.42 ( 1.12 - 1.81) 1.52 ( 1.10 - 2.09) PII vs PIII 0.002
3 2.04 ( 1.56 - 2.67) 1.90 ( 1.51 - 2.39 1.93 ( 1.46 - 2.55) PI vs PIII 0.001
2 2.54 ( 1.93 - 3.32) 2.58 ( 2.10 - 3.17) 2.95 ( 2.17 - 4.01)
1 3.51 ( 2.66 - 4.62) 3.90 ( 3.13 - 4.86) 4.74 ( 3.44 - 6.52)
* linear income trend not significant at 95% significance level.
Socioeconomic differences in amenable mortality by income and cause of death, men aged 25-74.
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http://www.biomedcentral.com/1472-6963/13/3death rates among the lowest income group. Widening in-
equalities in all cause and total disease mortality were
more modest. While a detailed analysis of gender differ-
ences in amenable mortality is beyond the scope of this
paper, amenable mortality rates remained higher in men
than women except for the highest income quintile. In
addition, the gender gap for amenable mortality was nar-
rower than that for all-cause or total disease mortality and
the reduction over time greater [33].
Since the initial studies of amenable mortality, the
age limit for amenable death has increased from 65 to
75 years in Western Europe, reflecting increased life ex-
pectancy [1]. The fall in premature deaths reflects lower
exposure to several risk factors, notably smoking, and
more effective medical care [34,35]. Despite the overall
decline in amenable mortality rates [36,37] the differen-
tial reductions by income groups and the persistent
socio-economic gradient illustrates the role of the health
system in perpetuating health inequalities [15,38]. Fur-
thermore, the gap between the lowest and second lowest
socio-economic group, or between those inside and out-
side of the workforce [16,39] suggests that health ser-
vices are not reaching the most disadvantaged. Although
the rate is smaller in other countries, the pattern of
excess amenable mortality due to chronic conditions
such as diabetes is similar to that found among in lower
income and minority ethnic groups elsewhere [7,15-18].
More detailed analysis of the relationship betweenamenable mortality rates and inequities in access, quality
and comprehensiveness of care is warranted.
Strengths and limitations
We applied current definitions of amenable mortality
[2,7] but our findings are based on comprehensive
and reliable individually based linked register data. The
level of confirmation of diagnosis at death by autopsy in
Finland is high by international comparison [40].
Our data also enabled us to consider the impact of
health service changes in the risk of amenable mortality
by socioeconomic group. In many studies, it is difficult
to determine the impact of changes in non-IHD mortal-
ity. We analysed IHD deaths separately for three rea-
sons. Firstly, because of the continuing debate about the
proportion of mortality from IHD that is amenable to
health service intervention. Secondly, the large number
of IHD deaths masks the pattern of amenable deaths
from other causes, and thirdly, because we analysed indi-
vidual level, not aggregate data, we could not exclude a
proportion of deaths from one condition. We were,
however, able to compare trends in IHD deaths with
those for amenable mortality as a whole and with other
causes of amenable mortality.
Data were incomplete in three areas. As with other
register based studies, we had no behavioural data al-
though alcohol and tobacco use clearly contribute to the
socio-economic gradient in premature deaths [41,42].
Table 3 Socioeconomic gradients in risk ratios for amenable mortality by income and cause of death, women aged
25-74
Period I: 1992 - 95 Period II: 1996 - 99 Period III: 2000 - 03 Period interactions
Income RR 95% CI RR 95% CI RR 95% CI P value
All cause mortality
5 1.00 1.00 1.00 PI vs PII <.001
4 1.27 (1.09 - 1.47 ) 1.28 (1.10 - 1.48 ) 1.29 (1.12 - 1.49 ) PII vs PIII 0.12
3 1.52 (1.34 - 1.73 ) 1.55 (1.36 - 1.76 ) 1.54 (1.34 - 1.77 ) PI vs PIII <.001
2 1.82 (1.60 - 2.06 ) 1.98 (1.74 - 2.25 ) 2.00 (1.70 - 2.35 )
1 2.53 (2.24 - 2.86 ) 2.98 (2.63 - 3.38 ) 3.26 (2.68 - 3.96 )
Total disease mortality
5 1.00 1.00 1.00 PI vs PII <.001
4 1.29 (1.11 - 1.50 ) 1.29 (1.11 - 1.49 ) 1.30 (1.14 - 1.48 ) PII vs PIII 0.24
3 1.53 (1.34 - 1.74 ) 1.55 (1.37 - 1.75 ) 1.53 (1.34 - 1.75 ) PI vs PIII <.001
2 1.80 (1.58 - 2.05 ) 1.93 (1.71 - 2.18 ) 1.95 (1.67 - 2.27 )
1 2.47 (2.18 - 2.81 ) 2.91 (2.58 - 3.28 ) 3.12 (2.58 - 3.76 )
Total amenable mortality
5 1.00 1.00 1.00 PI vs PII <.001
4 1.19 (1.04 - 1.38 ) 1.19 (1.04 - 1.38 ) 1.24 (1.12 - 1.38 ) PII vs PIII 0.05
3 1.37 (1.22 - 1.55 ) 1.43 (1.25 - 1.64 ) 1.47 (1.31 - 1.65 ) PI vs PIII <.001
2 1.52 (1.34 - 1.72 ) 1.62 (1.42 - 1.85 ) 1.77 (1.56 - 2.01 )
1 2.22 (1.97 - 2.51 ) 2.57 (2.26 - 2.92 ) 2.93 (2.53 - 3.40 )
Early detection and intervention
5 1.00 1.00 1.00 PI vs PII 0.04
4 1.17 (1.04 - 1.32 ) 1.19 (1.06- 1.35 ) 1.20 (1.08 - 1.34 ) PII vs PIII 0.17
3 1.33 (1.20 - 1.46 ) 1.39 (1.23 - 1.57 ) 1.38 (1.23 - 1.55 ) PI vs PIII <.001
2 1.40 (1.27- 1.54) 1.49 (1.32 - 1.67 ) 1.58 (1.41 - 1.76 )
1 1.80 (1.63 - 1.99 ) 1.99 (1.73- 2.29 ) 2.19 (1.93 - 2.48 )
- malignant neoplasm
5 1.00 * 1.00 1.00 PI vs PII 0.01
4 1.11 (0.96 - 1.29 ) 1.19 (1.01 - 1.40 ) 1.13 (0.96 - 1.32 ) PII vs PIII <.001
3 1.23 (1.08 - 1.39 ) 1.40 (1.98 - 1.65 ) 1.31 (1.09 - 1.56 ) PI vs PIII <.001
2 1.10 (0.96 - 1.26 ) 1.28 (1.08 - 1.52 ) 1.37 (1.14 - 1.63 )
1 1.06 (0.91 - 1.24 ) 1.29 (1.10 - 1.52 ) 1.57 (1.31 - 1.87 )
- hypertension and cerebrovascular disease
5 1.00 1.00 1.00 PI vs PII 0.11
4 1.29 (1.07 - 1.57 ) 1.23 (1.01 - 1.51 ) 1.49 (1.32 - 1.66 ) PII vs PIII 0.21
3 1.55 (1.31 - 1.82 ) 1.46 (1.26 - 1.71 ) 1.74 (1.57 - 1.94 ) PI vs PIII 0.01
2 1.87 (1.62 - 2.15 ) 1.92 (1.69 - 2.18 ) 2.26 (2.01 - 2.53 )
1 2.83 (2.46 - 3.26 ) 3.16 (2.72 - 3.66 ) 3.75 (3.15 - 4.45 )
Improved treatment and medical care
5 1.00 1.00 1.00 PI vs PII <.001
4 1.35 (0.91 - 2.01 ) 1.14 (0.73 - 1.77 ) 1.71 (1.11 - 2.64 ) PII vs PIII <.001
3 1.71 (1.17 - 2.49 ) 1.73 (1.15 - 2.61 ) 2.46 (1.82 - 3.31 ) PI vs PIII <.001
2 2.41 (1.66 - 3.51 ) 2.60 (1.76 - 3.83 ) 4.02 (2.90 - 5.56 )
1 5.44 (3.79 - 7.81 ) 6.70 (4.55 - 9.88 ) 11.41 (8.15 - 16.0 )
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Table 3 Socioeconomic gradients in risk ratios for amenable mortality by income and cause of death, women aged
25-74 (Continued)
- predominantly primary care
5 1.00 1.00 1.00 PI vs PII 0.41
4 1.20 (0.69 - 2.07 ) 1.52 (0.91 - 2.55 ) 2.14 (1.08 - 4.23 ) PII vs PIII <.001
3 1.56 (0.89 - 2.73 ) 1.99 (1.17 - 3.38 ) 3.43 (1.79 - 6.57 ) PI vs PIII <.001
2 2.85 (1.60 - 5.07 ) 3.55 (2.18 - 5.80 ) 8.42 (4.33 - 16.4 )
1 4.55 (2.79 - 7.42 ) 6.01 (3.88 - 9.33 ) 20.54 (11.4 - 36.8 )
- predominantly specialist care
5 1.00 1.00 1.00 PI vs PII 0.01
4 1.40 (0.90 - 2.18 ) 1.06 (0.65 - 1.73 ) 1.66 (1.05 - 2.62 ) PII vs PIII 0.06
3 1.74 (1.14 - 2.66 ) 1.70 (1.07 - 2.71 ) 2.32 (1.70 - 3.17 ) PI vs PIII <.001
2 2.37 (1.55 - 3.62 ) 2.51 (1.64 - 3.81 ) 3.58 (2.56 - 5.02 )
1 5.62 (3.72 - 8.49 ) 6.90 (4.50 – 10.6 ) 10.36 (7.14 - 15.0 )
Ischaemic heart disease
5 1.00 1.00 1.00 PI vs PII <.001
4 1.40 (1.24-1.58) 1.49 (1.30-1.70) 1.57 (1.39-1.78) PII vs PIII <.001
3 1.71 (1.54-1.90) 1.91 (1.67-2.18) 2.01 (1.77-2.29) PI vs PIII <.001
2 2.15 (1.92-2.40) 2.51 (2.18-2.90) 2.81 (2.43-3.25)
1 2.51 (2.27-2.80) 2.97 (2.61-3.39) 4.01 (3.51-4.59)
* linear income trend not significant at 95% significance level.
Socioeconomic differences in amenable mortality by income and cause of death. women aged 25-74.
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cohol related deaths results from policy interventions,
smoking cessation [43] and alcohol brief interventions
[44] are evidence based primary care treatments that
could be used widely among lower income groups in
Finland, but are not [45,46]. We also omitted healthcare-
associated deaths, as Statistics Finland does not identify
these separately in the Causes of Death register.
While we have access to high quality linked data, and
we checked the classification of deaths as amenable was
appropriate, researchers and policy makers continue to
debate the inclusion and exclusion of specific causes, the
relationship between evidence for intervention and im-
pact on amenable mortality rates and the boundary be-
tween health care and interventions excluded because
they are classified as multi-agency or health promotion.
All of these concerns are legitimate and are reflected in
the final report of the AMIEHS project : Avoidable mor-
tality in the European Union:
Towards better indicators for the effectiveness of health
systems. (http://amiehs.lshtm.ac.uk/publications/reports/
AMIEHS%20final%20report%20VOL%20I.pdf). We agree
with the authors’ caution to avoid direct attribution of a
causal relationship between deaths from amenable causes
and health system effectiveness but consider that our find-
ings are worrying and worthy of further investigation.
With this dataset, we were also unable to adjust for
socio-economic differences in incidence, in the treatabilityof disease associated with co-morbidity, or delays in seek-
ing medical care. In a universal healthcare system, differ-
ential changes in the incidence of treatable disease should
not affect the socio-economic gradient in amenable mor-
tality by virtue of being treatable. The extent of the socioe-
conomic gradient in multiple morbidity and its earlier
onset in primary care patients living in areas of multiple
deprivation has only recently been recognized [47]. It
seems plausible that the gradient in amenable mortality
reflects the earlier onset and treatability of multiple mor-
bidity in a less responsive health care environment rather
than a rise in the incidence of a single specific cause.
There is also evidence that lower socio-economic groups
have more limited access to treatment known to reduce
the risk of early death [48-50] even after adjustment for in-
dividual clinical characteristics. However, there is some
evidence that attention to populations with higher inci-
dence of disease in designing programmes of care can re-
duce some aspects of amenable mortality, for example
survival after myocardial infraction in South Asian popula-
tions in Scotland [51]. Attention to some of the previously
identified socioeconomic inequities in access to secondary
prevention and treatment of ischaemic heart disease, in-
cluding revascularization, may explain the more modest
increase in gradient in the lowest income group. Similarly,
data from the UK indicate that investing in common,
chronic conditions associated with amenable mortality
can improve outcome [52] although further work is
Figure 1 Amenable mortality rates for 25-74 years old by income quintiles in 1992-2003. See Additional file 1: Table S1.
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the socioeconomic and age gradient in multiple morbidity.
Since this was a cross-sectional study relating mortal-
ity to current income, we were unable to infer the direc-
tion of causation. Changes over time in the selection of
people with progressive illnesses and multiple morbidity
into lower income quintiles could partly explain the gra-
dients found.
Structural change in Finnish health services
Access to diagnosis and ongoing treatment regardless of
socioeconomic status or geography characterises universal
health systems. However gradients in amenable mortality,
particularly for conditions such as hypertension and dia-
betes persist [7,15,16,38,50]. At the start of the study
period, the 2-3 fold socioeconomic gradient in amenable
mortality in Finland was similar to that reported by other
comprehensive healthcare systems, despite differences in
funding, generosity of the social welfare system, and study
methodology. By the early 2000s in Finland, educational
inequalities in amenable mortality were greater than in
other Nordic countries [18] and income related differences
were substantially larger.
Inequalities in amenable mortality in Finland widened
during a period of structural and economic change. Dur-
ing the study period, municipal primary care received rela-
tively less investment than specialist services. Since the
late 1990s most people in stable employment receive pri-
mary healthcare from providers with which their employer
contracts and GPs no longer provide comprehensive pri-
mary care. The expansion in private specialist ambulatory
care services also provides more affluent groups with add-
itional opportunities to access care and have the costs par-
tially reimbursed by the social insurance system. The
design of these newer services may have changed the
help-seeking behaviour of men in higher income groups.
Our findings may also reflect the differential impact of co-
morbidity and complexity of need on the ability of people
with lower income to access acute and chronic care in an
increasingly complex Finnish healthcare system.
While most chronic conditions occur more frequently
among lower income groups, rising co-payments andlimited exemptions associated with the health service
reforms increase the financial burden of healthcare [53].
In addition, the Finnish health system has been slow to
adopt active methods of improving access and treatment
[54] for patients with chronic conditions in primary care.
Disease registers, call-recall systems, outreach services,
continuity of personal care, patient involvement in asses-
sing need and designing services are not widespread in
Finland.
Recent analysis of empirical and experimental research
has identified some interventions that may reduce socio-
economic inequalities in access to healthcare [55,56].
These include abolition of user fees, strengthening pri-
mary care so that it is universally available, expert-based,
and actively engages people from disadvantaged groups,
particularly those with chronic conditions.Conclusions
The pattern of amenable deaths in Finland for condi-
tions amenable to treatment and medical care indicates
a socio-economic gradient with the position of the low-
est income group worsening. These findings are consist-
ent with the expected impact of reducing equity of
access to primary medical care and enabling more afflu-
ent residents to access additional and specialist services.
We therefore urge careful consideration before the im-
plementation of any measures likely to impede equitable
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